BioTuesdays

Category - Markets

Capricor Therapeutics

HCW analyst assumes coverage of Capricor

H.C. Wainwright analyst Swayampakula Ramakanth has assumed coverage of Capricor Therapeutics (NASDAQ:CAPR) with a “buy” rating and $13 price target. The stock closed at $4.27 on Tuesday. Capricor has developed three...

CymaBay Therapeutics

Roth resumes coverage of CymaBay

Roth Capital Partners has resumed coverage of CymaBay Therapeutics (NASDAQ:CBAY) with a “buy” rating and $4 price target. The stock closed at $1.57 on Friday. “In our opinion, while catalysts for the next 12-to-18...

Galectin Therapeutics

Roth resumes coverage of Galectin Therapeutics

Roth Capital Partners resumed coverage of Galectin Therapeutics (NASDAQ:GALT) with a “buy” rating and $3 price target. The stock closed at $1.52 on Friday. “In our opinion, Phase 1 data demonstrated Galectin’s GR-MD...

Concert Pharma

Stifel starts Concert Pharma at buy

Stifel launched coverage of Concert Pharmaceuticals (NASDAQ:CNCE) with a “buy” rating and 12-month target price of $23. The stock closed at $11.20 on Friday. “Our bullish thesis centers on two key pipeline assets: AVP...

AtriCure Logo

JMP resumes coverage of AtriCure

JMP Securities resumed coverage of AtriCure (NASDAQ:ATRC) with a “market outperform” rating and $25 price target. The stock closed at $14.39 on Wednesday. “AtriCure is well positioned, in our view, to further develop...

Catalyst

Rodman starts Catalyst Biosciences at buy

Rodman & Renshaw initiated coverage of Catalyst Biosciences (NASDAQ:CLIO) with a “buy” rating and a 12-month price target of $3.50. The stock closed at $1.25 on Wednesday. Using its proprietary protease platform...

OpGen Logo

Rodman starts OpGen at buy

Rodman & Renshaw has initiated coverage of OpGen (NASDAQ:OPGN) with a “buy” rating and 12-month price target of $2.50. The stock closed at $1.56 on Tuesday. “In our view, the company’s QuickFISH assays, the latest...

Vascular Biogenics

HCW starts Vascular Biogenics at buy

H.C. Wainwright has launched coverage of Vascular Biogenics (NASDAQ:VBLT) with a “buy” rating and 12-month price target of $11. The stock closed at $4.10 on Tuesday. Vascular Biologics, also known as VBL Therapeutics or...

NeuroMetrix

Rodman starts NeuroMetrix at buy

Rodman & Renshaw has initiated coverage of NeuroMetrix (NASDAQ:NURO) with a “buy” rating and 12-month price target of $4.50. The stock closed at $1.74 on Tuesday. NeuroMetrix is a commercial-stage medical device...

Heat Biologics

Roth starts Heat Biologics at buy

Roth Capital Partners has initiated coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and $2.75 price target. The stock closed at 60 cents on Friday. “Heat Biologics possesses a portfolio of unique...